Adjuvant PRGN-2012 in Adult Patients With Recurrent Respiratory Papillomatosis

INCLUSION CRITERIA: * Age 18 years and older * Clinical diagnosis of RRP * Histological diagnosis of papilloma confirmed by pathology report from a CLIA-certified (or comparable) laboratory * Presence of laryngotracheal papillomas with or without pulmonary RRP * A history of 3 or more interventions in the last 12 months for control of RRP * Clinical performance status of ECOG of 0-1 * Willing to undergo endoscopic evaluation and operative interventions with biopsies in compliance with this protocol * No systemic therapy for RRP for at least 3 half-lives of the prior drug(s). A 30-day washout is required for systemic bevacizumab treatment * Participants who have received prior immunotherapy for RRP are permitted * Participants must have adequate organ and marrow function as defined below: * Sexually active subjects (men and women) of reproductive potential must agree to use two methods of contraception: one highly effective and one other effective method throughout vaccine treatment and for at least 120 days after vaccine treatment. Highly effective methods are defined as: Intrauterine device (IUD), hormonal (birth control pills, injections, implants), tubal ligation, and partner's vasectomy; other effective methods are defined as a latex condom, diaphragm, and cervical cap. * Seronegative for hepatitis B antigen, positive hepatitis B tests can be further evaluated by confirmatory tests (Hep B DNA quant, HBV viral load), and if confirmatory tests are negative, the pa…